Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Patients at least 18 years of age at the time of informed consent (women of childbearing potential must be practicing adequate contraception)
Patients with mean serum TG > 200 mg/dl (2.26 mmol/l) and < 700 mg/dl (7.91 mmol/l) as measured at 2 sequential visits during the dietary controlled baseline period (Visits 2 and 3 or Visits 3 and 3a) and having lower level within 25% of upper level (higher value minus lower value)/higher value < 0.25)
Patients willing and able to sign an informed consent form and follow the protocol

Exclusion Criteria:

Patients who are pregnant or nursing
Patients with evidence of hepatic dysfunction [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal (ULN), bilirubin greater than 1.5 times ULN, or cirrhosis] or renal dysfunction (serum creatinine greater than 140 μmol/l, or nephrotic syndrome) as measured during the baseline phase
Patients with uncontrolled diabetes mellitus (fasting glucose level above 11 mmol/l or HbA1C above 10%) as measured during the baseline phase
Patients with hypothyroidism that is not treated or not stable for at least 6 months prior to study entry
Patients with uncontrolled hypertension (systolic blood pressure above 160 mm Hg and/or diastolic blood pressure above 110 mm Hg)
Patients with systolic blood pressure above 140 mm Hg AND three or more of the following cardiovascular risk factors:
Current cigarette smoker
HDL-C < 40 mg/dL (1.04 mmol/L)
Coronary heart disease in male first degree relative < 55 years of age
Coronary heart disease in female first degree relative < 65 years of age
Male age 45 years or older
Female age 55 years or older
Patients with known hyperuricemia or with a history of gout
Patients with an active peptic ulcer
Patients with known coronary artery disease, cerebrovascular disease or peripheral arterial disease that has previously required percutaneous coronary intervention or surgical intervention
Patients with known intolerance or allergy to niacin
Patients consuming more than 10 alcoholic drinks per week
Patients with a history of drug abuse
Patients receiving any lipid modifying agent within 4 weeks of entry into the baseline period
Patients participating in another clinical trial within 30 days of entry into the baseline period
Patients considered to be non-compliant to study medication (< 80% study medication) or diet during the placebo-baseline phase
Patients for whom the investigator determines that the study would not be appropriate